Ken Griffin Enanta Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.05 - $16.54 $56,280 - $92,624	-5,600 Reduced 53.85%	4,800 $49,000
Q2 2024 Aug 14, 2024	BUY	$11.43 - $17.02 $11,430 - $17,020	1,000 Added 10.64%	10,400 $134,000
Q1 2024 May 15, 2024	BUY	$10.08 - $17.46 $75,600 - $130,950	7,500 Added 394.74%	9,400 $164,000
Q4 2023 Feb 14, 2024	BUY	$8.18 - $10.78 $8,998 - $11,858	1,100 Added 137.5%	1,900 $17,000
Q3 2023 Nov 14, 2023	SELL	$11.09 - $22.13 $11,090 - $22,130	-1,000 Reduced 55.56%	800 $8,000
Q2 2023 Aug 14, 2023	SELL	$20.68 - $39.85 $1.12 Million - $2.16 Million	-54,300 Reduced 96.79%	1,800 $38,000
Q1 2023 May 15, 2023	SELL	$38.82 - $54.59 $3.3 Million - $4.65 Million	-85,100 Reduced 60.27%	56,100 $2.27 Million
Q4 2022 Feb 14, 2023	BUY	$40.77 - $53.73 $1.24 Million - $1.63 Million	30,300 Added 27.32%	141,200 $6.57 Million
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $2 Million - $2.96 Million	41,500 Added 59.8%	110,900 $5.75 Million

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $177M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.